Biocept Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- S&P and Nasdaq dip as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- S&P and Nasdaq dip as investors focus on tech earnings
Biocept (BIOC) Tops Q1 EPS by 19c
May 12, 2021 4:24 PM EDTBiocept (NASDAQ: BIOC) reported Q1 EPS of $0.19, $0.19 better than the analyst estimate of $0.00. Revenue for the quarter came in at $17.8 million versus the consensus estimate of $13.67 million.
We are reporting profitability for the second consecutive quarter on revenues of $17.8 million, as our dedicated Biocept team continued to serve our community with COVID-19 RT-PCR testing featuring exceptional customer service and rapid turnaround times, said Michael Nall, Biocepts President and CEO. These outstanding financial results support further advancements with our core oncology business and more specifically our focus on neuro-oncology as we build for a strong... More
